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Abstract 
Background: To determine the value of extent of 
liver injury as a baseline predictor of response to 
conventional interferon plus ribavirin for chronic 
hepatitis C Genotype 3 . 
Methods: In this descriptive study treatment naive 
hepatitis C patients (n=489) underwent serum 
Alanine Aminotransferase (ALT) measurement and a 
liver biopsy to assess for hepatic steatosis and 
Histology Activity Index (HAI). Six  months 
conventional interferon plus ribavirin therapy was 
given to all and the significance of above mentioned 
parameters as predictors of response in terms of 
Sustained Virological Response (SVR) and End of 
Treatment  Response (ETR)  was  analyzed.  Chi-
square test and regression analysis were used to 
calculate the results with a significant P value < 0.05. 
Results: Male individuals constituted 31.1% 
(n=152) of the population while 68.9% (n=337) were 
females. Mean Alanine Aminotransferase level was 
73.74 ± 65.27 IU/l.SVR was achieved by 61% (n=298) 
individuals while ETR by 83.4% (n=408). Mild 
hepatic inflammation and fibrosis i-e-, low HAI (≤8) 
turned out to be a significant predictor of both a 
good ETR (p=0.00) and SVR (p=0.00). Minimal to 
mild degree of steatosis (≤33%) was a predictor of 
better SVR (0.00). Baseline ALT level was not 
significantly associated with response rate (p=0.76). 
Conclusion: Lower extent of hepatic steatosis 
(≤33%) and low HAI (≤8) is a significant predictor of 
better response to conventional interferon 
combination therapy for HCV Genotype 3. Hepatic 
steatosis >66% and HAI > 12 predicts failure to 
respond. 
Key Words: Conventional interferon, Ribavirin, 
Histological Activity Index, Steatosis, End of 
Treatment Response, Sustained Virological 
Response, Hepatitis C. 
Introduction 
It is impossible to really know the origins of hepatitis 
C. However given the nature of the evolution of all 
viruses, hepatitis C has probably been around for 
hundreds of thousands of years or more. Chronic 
infection with hepatitis C virus (HCV) is a global 
health problem and is estimated to affect up to 3% of 
the world population. 1Treatment of HCV infected 
patients with interferon combination therapy remains 
suboptimal. Various clinical, laboratory and 
histological parameters are used to predict non-
response to treatment. 2 Age, gender, Body Mass 
Index, steatosis, biochemical markers and Histological 
Activity Index (HAI) are some of them. The role of 
baseline biochemical parameters and hepatocyte injury 
towards achieving better response is a debatable topic. 
2- 5The objective of our study was to determine the 
importance of hepatic steatosis, serum Alanine 
Aminotransferase (ALT) levels and Histological 
Activity Index as a predictor of response to 
conventional interferon plus ribavirin therapy in 
treating chronic HCV infection in Pakistan. This has 
become important because predictors of response to 
therapy serve as a decision tool for physicians to help 
identify patients who are likely or unlikely to achieve a 
Sustained Virological Response (SVR). This will help 
to consider pre-treatment counseling in those patients 
with a reduced likelihood of successful therapy via 
risk stratification considering financial constraints of 
general population exposed to HCV in Pakistan. 
Moreover, such patients can be offered newer 
antivirals right at the beginning.  
 
Patients and Methods  
Interferon naïve adults of both gender and all ages 
seen at liver clinic, KRL hospital with chronic Hepatitis 
C genotype-3 infection were included in the study. 
Patients were required to have a detectable serum 
HCV RNA (ribonucleic acid) on Polymerase Chain 
Reaction (PCR) at presentation. They were also 
required to have a negative pregnancy test and having 
minimum values for hemoglobin of 120 g/l for women 
and 135 g/l for men; leukocyte count ≥ 4x109/l and 
platelet count ≥ 150 x 109/l .  It  was  also  required  
that  they  have  normal  bilirubin,  albumin,  urea  and 
creatinine  levels. Patients were excluded if they had 
decompensated cirrhosis, other causes of liver disease 
and/or were Hepatitis B surface antigen or Human 
Immunodeficiency Virus positive. Alcoholics, patients 
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with seizure disorders, cardiovascular disease, 
hemoglobinopathies, thyroid disease, clinically 
relevant depression or any other psychiatric disease 
were also excluded. Other exclusion criteria included 
hemophilia, poorly controlled diabetes, autoimmune 
disease, previous organ transplant and/ or being 
unable to use contraception. 6 
The primary measure of efficacy was Sustained 
Virological Response. The other parameter used to 
depict effectiveness was End of Treatment Response 
(ETR). Extent of liver injury was assessed on the basis 
of HAI, degree of steatosis and biochemical marker for 
hepatocyte damage i-e-, Alanine Aminotransferase 
levels. 
Treatment naïve, HCV RNA positive patients with 
chronic hepatitis C were given conventional interferon 
alpha 2b (3 Million IU) thrice weekly plus ribavirin 
(1000-1200 mg/day) for 24 weeks. Treatment was 
stopped in 3 individuals due to serious side effects. 
Rest of the 36 either did not come for follow-up or had 
important data missing and were excluded from the 
study results.  Response to treatment was assessed via 
ETR at 24 weeks and via SVR at 48 weeks, both with 
Qualitative PCR for HCV RNA having lower limit of 
detection as 50 IU/ml. 6  Patients who received 80% of 
conventional dose and duration of therapy were 
declared to have completed treatment. 6 ETR was 
defined as negative qualitative PCR at end of 
treatment while SVR was defined as negative PCR six 
months after completion of therapy. Those achieving 
ETR and/ or SVR were designated as Complete 
Responders (CR) at respective points in time. Patients 
with positive PCR at end of treatment and also six 
months after treatment completion were declared as 
Non-Responders (NR). Those with positive PCR at end 
of treatment and negative PCR six months after 
completion of therapy were defined as Late 
Responders. Break-Through Non-Responders (BTNR) 
were the ones having reappearance of detectable HCV 
RNA once eradicated while on therapy. Relapse (R) 
was defined as negative end of treatment PCR but 
positive PCR after six months of completion of 
treatment. Definitions used were as per AASLD 
(American Association for the Study of Liver Diseases) 
guidelines.8 Individuals ending up as Complete 
Responders (CR) were the ones with good response 
rate while Non-Responders (NR) and Relapsers (R) 
were the ones with poor response. 
Liver biopsies were performed in the interventional 
suite at KRL. For percutaneous biopsy, abdomen was 
prepared and draped in standard sterile fashion and a 
core biopsy of liver was performed under local 
anesthesia using an 18 G fine cut standard Guillotine 
type needle at the point of surface marking 
determined by ultrasonography. Presence of steatosis, 
which was graded as absent (0%), minimal to mild 
(1%–33%), moderate (>33%–66%) or severe (>66%) 
based on the classification defined by Kleiner et al. 9 
The extent of liver inflammation and fibrosis was 
defined using the Histologic Activity Index (HAI) i-e-, 
no (0), minimal (1-4), mild (5-8), moderate (9-12) or 
marked/severe (13-18). 10Multivariate analysis was 
done by forward stepwise logistic regression keeping a 
significant p value < 0.05. 
 
Results 
Male individuals constituted 31.3% (n=152) of the 
population while 68.9% (n=337) were females. Mean 
age of the cohort was 44.33 ± 9.11 years and mean BMI 
was 27.51 ± 7.04 kg/m2. Mean base line hemoglobin 
was 13.2 ± 1.84 g/l, platelet count was 227 ± 84 x 109 /l 
and mean leukocyte count was 6.7 ± 1.75 x 109 / l. 
Mean Alanine Aminotransferase level was73.74 ± 
65.27 IU/l. Sustained Virological Response was 
achieved by 61% (n=298) individuals while End of 
Treatment Response by 83.4% (n=408) (Table 1 &2). 
All subjects had some degree of steatosis and hepatic 
inflammation on biopsy. None had minimal HAI. The 
spectrum of HAI varied from ‘mild’ to ‘marked’ while 
that of steatosis from ‘minimal’ to ‘severe’ (Table 3). 
On univariate analysis, mild hepatic inflammation and 
fibrosis i-e-, low HAI (≤8) turned out to be a significant 
predictor of both a good ETR as well as SVR. Minimal 
to mild degree of steatosis (≤33%) was a predictor of 
better SVR but not ETR (Table 3). On multivariate 
analysis, mild hepatic inflammation and fibrosis 
(HAI≤8) was a significant predictor of good ETR and 
SVR. Minimal to mild degree of steatosis (≤33%) was a 
predictor of better SVR but a poor predictor of ETR 
(Table 2 &3). Baseline  Alanine  Aminotransferase  
level  was  not  significantly  related  to  either  SVR 
(p=0.11) or ETR (p=0.76). Grades of hepatic steatosis 
varied from  mild to severe (Figure 1). Grades of  
hepatic inflammation and fibrosis varied from 
minimal to marked  (Figure 2) 
 
 
Table 1: Outcome at end of treatment response  
(ETR) 
Response No (%) 
Complete response 408 (83.4) 
Breakthrough non responders 69(14.1) 
Non responders  12 (2.4) 
Journal of Rawalpindi Medical College (JRMC); 2016;20(2):139-143 
 141 
 
Figure 1: Grades of hepatic steatosis: (Courtesy histopathology 
department KRL hospital) A: No steatosis (0%), B: Mild 
steatosis (1-33%), note the few fat laden cells (black 
arrowheads), spared liver tissue (white arrowhead), C: 
Moderate steatosis (>33-66%);fat laden cells (black 
arrowheads), spared liver tissue (white arrowhead), D: Severe 
steatosis (>66%); the whole field studded with fat laden cells.  
 
 
Figure 3: Grades of hepatic inflammation and fibrosis (HAI): 
(Courtesy of histopathology department of KRL Hopsital): 
Microscopic view, H & E stain (40X). A: No (0), B: Minimal to 
mild (1-8), note few lymphocytes with few fat laden cells, C: 
Moderate (9-12), note lymphocyte aggregate (black arrowheads) 
and moderate hepatitis with fibrosis (white 
arrowhead);D:Marked(13-18); the marked/severe fibrosis with 
fibrous septum formation; HAI=Histologic Activity Index.  
 
Table 2: Outcome at sustained viral response 
(SVR) 
Response No(%) 
Complete response 298 (61) 
Relapsers 110 (22.5) 
Non responders  81 (16.5) 
Table 3: Baseline steatosis as a predictor of 
response to interferon combination therapy 
Steatosis as predictor of ETR p value 
Parameter 
CR % 
(n) 
BTNR 
% (n) 
NR % 
(n) 
p-U p-M 
Minimal 
to mild 
79.6 
(325) 
31.8 
(22) 
16.683 
(2) 
0.99 
0.81 Moderate 
13.9 
(57) 
36.2 
(25) 
25.0 
(3) 
0.79 
Severe 
6.3 
(26) 
31.8 
(22) 
58.3 
(7) 
0.32 
Total 
100 
(408) 
100 
(69) 
100 
(12) 
- - 
 
Steatosis as predictor of SVR p- value 
Parameter 
CR % 
(n) 
R % 
(n) 
NR % 
(n) 
p-U p-M 
Minimal 
to mild 
70.1 
(209) 
26.3 
(29) 
14.8 
(12) 
0.00* 
0.00* Moderate 
19.7 
(59) 
34.5 
(38) 
29.6 
(24) 
0.05 
Severe 
10.0 
(30) 
39.0 
(43) 
55.5 
(45) 
0.03* 
Total 
100 
(298) 
100 
(110) 
100 
(81) 
- - 
ETR=End of Treatment response; SVR= Sustained 
Virological Response.CR=Complete Responders; 
BTNR=Break-Through Non-Responders; NR=Non-
Responders; R=Relapser;* = statistically significant; 
U=univariate; M=multivariate. 
 
Discussion 
Chronic infection with hepatitis C virus is a global 
health problem. The burden of disease in our region is 
far more than the western community. 1  Treatment of 
chronic HCV infection with interferon plus ribavirin 
combination therapy remains suboptimal. Different 
studies describe predictors of response to interferon 
combination therapy to select patients who would 
benefit most from the treatment. 2  Our study describes 
significance of hepatic steatosis, hepatic inflammation 
and fibrosis and serum ALT level as a predictor of 
response to interferon therapy. According to different 
researchers, hepatic steatosis has a negative influence 
on SVR. SVR for patients with significant steatosis is 
lower. 3,11  In our study, univariate analysis showed 
that lower degree of hepatic steatosis (≤33%) is a 
significant predictor of achieving better SVR (p=0.00). 
However, it was found to be a poor predictor of ETR 
(p=0.99) . Multivariate analysis yielded similar results . 
According to Kojima et al. (2001), histological 
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improvement is more rapid in patients who achieve 
SVR than in those who biochemically improve but 
remain seropositive for HCV. 5  Only the ones with 
SVR exhibit complete cure histologically . While in 
patients whose ALT level decrease but SVR is not 
achieved, liver fibrosis remains unchanged or shows 
progression. 5, 6  Univariate analysis for our study 
showed mild hepatic inflammation and fibrosis i-e-, 
low HAI (≤8) to be a significant predictor of better ETR 
(p=0.00) as well as better SVR (p=0.00) (Table 2). Low 
HAI (≤8) was found to be a significant predictor of 
achieving better ETR and SVR on multivariate analysis 
as well (p=0.00) (Table 2). On the other hand, high 
HAI i-e-, >12 was associated with a higher chance of 
eventually ending up (at SVR stage) as a non-
responder (p=0.00) (Table 2). 
 
Table 4: Baseline hepatocellular inflammation and 
 fibrosis (HAI) as a predictor of response to 
interferon  combination therapy 
HAI as predictor of ETR p value 
Parameter 
CR  
% (n) 
BTNR  
% (n) 
NR 
% 
(n) 
p-
U 
p-M 
Minimal to 
mild 
88.7 
(362) 
17.3 
(12) 
8.3 
(1) 
0.0
0* 
0.00
* 
Moderate 9.0 (37) 
26.0 
(18) 
16.6 
(2) 
0.0
4* 
Marked/Se-
vere 
2.2 (9) 
56.5 
(39) 
75.0 
(9) 
0.0
1* 
Total 100408) 100(69) 100 
(12) 
- - 
 
HAI as predictor of SVR p value 
Parameter 
CR  
% (n) 
R % 
(n) 
NR 
 % 
(n) 
p-U 
p-
M 
Minimal to 
mild 
77.5 
(231) 
29.0 
(32) 
11.1 
(9) 
0.00
* 
0.0
0* 
Moderate 
15.1 
(45) 
32.7 
(36) 
23.4 
(19) 
0.06 
Marked/Se-
vere 
7.3 (22) 
51.8 
(42) 
65.4 
(53) 
0.01
* 
Total 
100 
(298) 
100 
(110) 
100 
(81) 
- - 
ETR=End of Treatment response; SVR= Sustained 
Virological Response.CR=Complete Responders; 
BTNR=Break-Through Non-Responders; NR=Non-
Responders; R=Relapsers; * = statistically significant; 
U=univariate; M=multivariate. 
 
According to Hung et al. (2002), delayed 
normalization of serum ALT levels does not predict 
SVR in patients treated with combination of interferon 
plus ribavirin. 4  They showed that there is no 
difference in SVR between patients with or without 
early normalization of ALT level. 4  To our observation, 
the significance of baseline ALT as an independent 
predictor of response has not been studied previously 
in South-East Asia where viral characteristics differ 
from rest of the world i-e-, genotype 3 is more 
common. In our study, baseline ALT was not a 
significant predictor of either achieving an ETR 
(p=0.76) or SVR (p=0.11). The value of this biochemical 
marker has been controversial 2, 4  in the past and 
based on our results, we would like to make the 
comment that baseline ALT is a poor predictor of 
response to interferon combination therapy.  
A lower degree of steatosis and HAI can significantly 
predict a better response to antiviral therapy. Greater 
extent of baseline hepatic damage i-e-, higher HAI 
(>12) and marked steatosis (>66%) are associated with 
a higher possibility of failure to achieve an SVR. Based 
on these observations, pre-treatment counseling can be 
done in patients unlikely to achieve an SVR and better 
antivirals can be opted for in the first place. This will 
not only serve to reduce the cost of treatment but also 
spare them of the untoward effects of multiple 
treatments that might have to be used in case of failure 
of one type. Moreover, such patients can be offered 
newer antivirals right at the beginning with the aim to 
achieve better outcomes including sofosbuvir. By 
having a predictive risk assessment via baseline HAI 
and steatosis, risk stratification can be done and 
patients can be offered treatment accordingly as all 
patients in a third world country like Pakistan cannot 
afford to follow best available treatment strategy. Such 
a risk categorization can help reduce the burden of 
cost on poor community while providing them 
intelligently with suitable treatment plans. 
 
Conclusion 
Lower extent of steatosis (≤33%) and low HAI (≤8) is a 
significant predictor of better response to conventional 
interferon combination therapy for HCV Genotype 3. 
Hepatic steatosis >66% and HAI >12 predicts failure to 
respond. 
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